Assessment of Tenofovir effects on bone mineral density in chronic Hepatitis B patients non infected with HIV

• Grant number: 16/19284-7
• Support Opportunities: Scholarships in Brazil - Doctorate
• Start date: May 01, 2017
• End date: July 31, 2019
• Field of knowledge: Health Sciences - Nutrition
• Agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Anderson Marliere Navarro
• Grantee: Renata Dessordi
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

Hepatitis B is a major public health problem worldwide and is associated with considerable mortality rates. In order to prevent or delay the deleterious effects of chronic hepatitis B virus infection, patients should be followed closely and the antiviral therapy indicated according to specific recommendations. The available treatment inhibits viral replication and delay or interrupts the progression of liver inflammation and fibrosis. However, oral medications, also called nucleoside/nucleotide analogues, are long-term therapy and have possible side effects. Among these side effects, prolonged use of Tenofovir may lead to bone mineral density loss. This adverse effect has been well studied in HIV patients since Tenofovir is also used as antiretroviral drug. There are few studies assessing the effects of Tenofovir on bone health of hepatitis B monoinfected patients. The present project aims to evaluate the effects of Tenofovir, compared with those of other nucleoside/nucleotide analogues, on bone mineral density of hepatitis B patients. In these patients, bone mineral density will be evaluated by densitometry concomitantly with serum markers of bone metabolism. The patients will be grouped into categories according to the use of Tenofovir, in a group, or other nucleoside/nucleotide analogues, in other group. A third group, composed of hepatitis B infected subjects who did not use nucleoside/nucleotide analogues previously will serve as controls. Data collection will be performed after approval of the protocol study and also the informed consent by the research ethics committee. Statistical analysis will be performed by the use of parametric or non-parametric tests and correlation between variables according to their characteristics. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

RENATA DESSORDI; RODRIGO DE CARVALHO SANTANA; ANDERSON MARLIERE NAVARRO. Influence of antiretroviral therapy on bone metabolism of patients with chronic hepatitis B: a review. Revista da Sociedade Brasileira de Medicina Tropical, v. 52, 2019-10-03. (16/19284-7)

DESSORDI, RENATA; WATANABE, LIGIA MORIGUCHI; GUIMARAES, MARIANA PALMA; ROMAO, ELEN ALMEIDA; CANDOLO MARTINELLI, ANA DE LOURDES; SANTANA, RODRIGO DE CARVALHO; NAVARRO, ANDERSON MARLIERE. Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use. SCIENTIFIC REPORTS, v. 11, n. 1, MAY 13 2021. (16/19284-7)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

DESSORDI, Renata. Evaluation of the effects of tenofovir on bone mineral density in patients with chronic hepatitis B not infected with HIV. 2019. Doctoral Thesis - Universidade Estadual Paulista (Unesp). Faculdade de Ciências Farmacêuticas. Araraquara Araraquara.